US relaxes marijuana regulations as industry faces financial struggles

The US government has reduced restrictions on marijuana, particularly for medicinal purposes. The changes were made by the Trump administration.

In 2020, the FDA approved a new medication containing cannabidiol (CBD), which is derived from cannabis plants. This approval marked a significant shift in how the federal government views CBD, as it was previously considered a controlled substance.

The US Department of Health and Human Services has reclassified certain types of marijuana, including those used for medicinal purposes, as “less-dangerous” than previously classified substances. These changes are intended to facilitate research and development of new treatments using cannabis-based products.

The FDA has also approved several cannabis-derived medications, which have been shown to be effective in treating various conditions, such as epilepsy and multiple sclerosis. The approval of these medications is a result of the reclassification of certain types of marijuana by the US government.

Additionally, the US Department of Agriculture (USDA) has announced plans to allow the sale of hemp-based products, including CBD-infused foods and cosmetics, without prior approval from the FDA. This move is intended to promote the growth of the hemp industry and provide more options for consumers.

The changes made by the Trump administration are aimed at promoting research and development of new treatments using cannabis-based products, as well as providing more options for consumers.

Source: Google News World